• Kuvat N, Tanriverdi H, Armutcu F. The relationship between obstructive sleep apnea syndrome and obesity: A new perspective on the pathogenesis in terms of organ crosstalk. Clin Respir J 2020; 14: 595-604. doi: 10.1111/crj.13175.
• Armutcu F. Organ crosstalk: the potent roles of inflammation and fibrotic changes in the course of organ interactions. Inflamm Res. 2019; 68(10): 825‐39. doi: 10.1007/s00011-019-01271-7.
• Isono S. Obesity and obstructive sleep apnoea: mechanisms for increased collapsibility of the passive pharyngeal airway. Respirology. 2012; 17(1): 32-42. doi: 10.1111/j.1440-1843.2011.02093.x.
• Kwon CH, Rhee EJ, Song JU et al. Reduced lung function is independently associated with increased risk of type 2 diabetes in Korean men. Cardiovasc Diabetol. 2012; 11: 38. doi: 10.1186/1475-2840-11-38.
• Song JU, Jang Y, Lim SY, et al. Decreased lung function is associated with risk of developing non-alcoholic fatty liver disease: A longitudinal cohort study. PLoS One. 2019; 14(1): e0208736. doi: 10.1371/journal.pone.0208736
• Katsiki N, Stoian AP, Steiropoulos P, Papanas N, Suceveanu AI, Mikhailidis DP. Metabolic Syndrome and Abnormal Peri-Organ or Intra-Organ Fat (APIFat) Deposition in Chronic Obstructive Pulmonary Disease: An Overview. Metabolites 2020; 10(11): 465. doi: 10.3390/metabo10110465
• Xu S, Wan Y, Xu M, et al. The association between obstructive sleep apnea and metabolic syndrome: A systematic review and meta-analysis. BMC Pulm. Med. 2015; 15: 105. doi: 10.1186/s12890-015-0102-3.
• Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes. Rev. 2013; 14: 417-31. doi: 10.1111/obr.12020.
• Jin S, Jiang S, Hu A. Association between obstructive sleep apnea and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Sleep Breath. 2018; 22: 841-51. doi: 10.1007/s11325-018-1625-7.
• Lee HW, Lee DH, Lee JK, et al. Pulmonary function is associated with fibrosis severity in patients with biopsy-proven nonalcoholic fatty liver disease. Liver Int. 2020 Dec; 40(12): 3008-17. doi: 10.1111/liv.14626.
• Akyol S, Lu J, Akyol O, et al. The role of electronegative low-density lipoprotein in cardiovascular diseases and its therapeutic implications. Trends Cardiovasc Med. 2017; 27(4): 239-46. doi: 10.1016/j.tcm.2016.11.002.
• Hsu JF, Chou TC, Lu J, et al. Low-density lipoprotein electronegativity is a novel cardiometabolic risk factor. PLoS One. 2014; 9(9): e107340. doi: 10.1371/journal.pone.0107340.
• Chang CT, Wang GJ, Kuo CC, et al. Electronegative Low-density Lipoprotein Increases Coronary Artery Disease Risk in Uremia Patients on Maintenance Hemodialysis. Medicine (Baltimore). 2016; 95(2): e2265. doi: 10.1097/MD.0000000000002265.
• Sowka A, Dobrzyn P. Role of perivascular adipose tissue-derived adiponectin in vascular homeostasis. Cells. 2021; 10(6): 1485. doi: 10.3390/cells10061485.
• Kakino A, Fujita Y, Ke LY, Chan HC, Tsai MH, Dai CY, et al. Adiponectin forms a complex with atherogenic LDL and inhibits its downstream effects. J Lipid Res. 2020; 62: 100001. doi: 10.1194/jlr.RA120000767.
• Armutcu F. Akyol S, Vural H. Metabolic syndrome is an important cornerstone in the health-disease line and pathological organ interaction. J Cell Signal. 2020; 1(3): 70-5. doi: 10.33696/Signaling.1.014.
• Akyol O, Chowdhury I, Akyol HR, et al. Why are cardiovascular diseases more common among patients with severe mental illness? The potential involvement of electronegative low-density lipoprotein (LDL) L5. Medical Hypotheses 2020; 142: 109821. doi: 10.1016/j.mehy.2020.109821.

Vancouver

Vural H, Akyol S. Electronegative LDL: Could it be a Potential Biomarker for Organ Interactions?. J CLIN EXP INVEST. 2021;12(4):em00782. https://doi.org/10.29333/jcei/11271

APA

Vural, H., & Akyol, S. (2021). Electronegative LDL: Could it be a Potential Biomarker for Organ Interactions?. Journal of Clinical and Experimental Investigations, 12(4), em00782. https://doi.org/10.29333/jcei/11271

AMA

Vural H, Akyol S. Electronegative LDL: Could it be a Potential Biomarker for Organ Interactions?. J CLIN EXP INVEST. 2021;12(4), em00782. https://doi.org/10.29333/jcei/11271

Chicago

Vural, Huseyin, and Suheyla Akyol. "Electronegative LDL: Could it be a Potential Biomarker for Organ Interactions?". Journal of Clinical and Experimental Investigations 2021 12 no. 4 (2021): em00782. https://doi.org/10.29333/jcei/11271

Harvard

Vural, H., and Akyol, S. (2021). Electronegative LDL: Could it be a Potential Biomarker for Organ Interactions?. Journal of Clinical and Experimental Investigations, 12(4), em00782. https://doi.org/10.29333/jcei/11271

MLA

Vural, Huseyin et al. "Electronegative LDL: Could it be a Potential Biomarker for Organ Interactions?". Journal of Clinical and Experimental Investigations, vol. 12, no. 4, 2021, em00782. https://doi.org/10.29333/jcei/11271